VSA 001
Alternative Names: VSA-001Latest Information Update: 20 Jun 2023
At a glance
- Originator Visirna Therapeutics
- Class Cardiovascular therapies; Small interfering RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cardiovascular disorders; Metabolic disorders